A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 8, 2019

Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan

Tokyo: January 8, 2019 - Toa Eiyo Ltd. (President: Atsuo Takahashi, Ph.D., “Toa Eiyo”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) announced today that Toa...

Read more about Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan
Dec 21, 2018

Approval of Suglat® Tablets, Selective SGLT2 Inhibitor, for Additional Indication of type 1 diabetes mellitus and Additional dosage and administration in Japan

Tokyo, December 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi Tomiyama,...

Read more about Approval of Suglat® Tablets, Selective SGLT2 Inhibitor, for Additional Indication of type 1 diabetes mellitus and Additional dosage and administration in Japan
Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK, Dec. 20, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES...

Read more about Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Dec 14, 2018

Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -

TOKYO, December 14, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it exercised, and closed on its exclusive option to...

Read more about Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -
Dec 11, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

TOKYO – December 11, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that XOSPATA® (generic name: gilteritinib) is now...

Read more about Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts